Quick Takeaways
- Commodore Capital LP has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $431,486,624.
- Recent insider filing activity is available below.
- Info
- Portfolio
- Significant Ownership
- Insider Ownership
Insider Trading & Ownership of Commodore Capital LP
- Location
- New York, NY
- Summary
- The estimated value of insider holdings of Commodore Capital LP is at least $431,486,624 dollars as of 12 Jan 2024. Commodore Capital LP is the 10%+ Owner of Ambrx Biopharma Inc. and owns shares of Ambrx Biopharma Cayman, Inc. stock worth about $330.04M. Commodore Capital LP is the 10%+ Owner of Vera Therapeutics, Inc. and owns shares of Vera Therapeutics, Inc. (VERA) stock worth about $79.2M. Commodore Capital LP is the 10%+ Owner of Enliven Therapeutics, Inc. and owns shares of Enliven Therapeutics, Inc. (ELVN) stock worth about $21.93M. Commodore Capital LP is the 10%+ Owner of Satsuma Pharmaceuticals, Inc. and owns shares of Satsuma Pharmaceuticals, Inc. stock worth about $325.7K.
- Signature
- /s/ Michael Kramarz, Managing Partner
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Commodore Capital LP and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Ambrx Biopharma Inc. ($330,035,790).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Commodore Capital LP
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| AMAM | Ambrx Biopharma Inc. | 10%+ Owner | $330,035,790 | 23 Feb 2023 | ||
| VERA | Vera Therapeutics, Inc. | 10%+ Owner | $79,200,000 | 10 Jan 2024 | ||
| ELVN | Enliven Therapeutics, Inc. | 10%+ Owner | $21,925,166 | 23 Feb 2023 | ||
| STSA | Satsuma Pharmaceuticals, Inc. | 10%+ Owner | $325,668 | 14 Nov 2022 | ||
| VTGN | Vistagen Therapeutics, Inc. | 10%+ Owner | 04 Oct 2023 |
Insider Transactions Reported by Commodore Capital LP:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.